Novo Nordisk A/S (NVO) is a Healthcare company in the Drug Manufacturers - General industry with a 84% Strong Buy Score. Key strengths include Gross Margin (82.0%), Net Margin (35.3%), Return on Equity (59.8%). The score on this page is a five-factor screen — revenue growth, gross margin, net margin, return on equity and debt-to-equity — each scored against fixed thresholds from a neutral starting point of 50%. The eight-section analysis, including moat, free cash flow, dilution and valuation, runs in the full report.
This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.
4 of the inputs in our model moved NVO's score away from the neutral baseline of 50%, landing it at 84% (Strong Buy). Each one below is a specific figure from Novo Nordisk A/S's reported financials, not a judgement call:
4 data points sit outside the score itself but bear on Novo Nordisk A/S's next few quarters. They are reported here as observations, not predictions:
1 measurable risk showed up in Novo Nordisk A/S's numbers. This is not a complete list of what could go wrong — only what is visible in the data we score:
Novo Nordisk A/S's liquidity and cash generation as of the most recent filing — note the cash position of $44.98B against $140.13B of debt:
Figures are drawn from Novo Nordisk A/S's most recent balance sheet and cash flow statement as filed with the SEC. See the filings themselves.
Institutional investment managers with >$100 M in qualifying assets must disclose their equity positions quarterly on SEC Form 13F — typically within 45 days of quarter-end. Search those filings below to see which hedge funds, mutual funds, and asset managers reported NVO as a holding, how many shares they held, and how positions changed quarter over quarter.
We do not answer that question for you, and we do not publish buy or sell calls. What we publish is a score: NVO rates 84% on our five-factor fundamentals screen, which puts it in the "Strong Buy" band. Everything below explains how it got there so you can disagree with it.
Novo Nordisk A/S clears our thresholds on most of what we measure. The strongest readings are gross margin (82.0%) and net margin (35.3%). Nothing in the data we score currently works against it.
Novo Nordisk A/S reported revenue growth of 2.1% year over year, against a Drug Manufacturers - General peer set where scale and pricing power vary widely. Growth that slow contributes little to the score on its own; margins and capital efficiency carry more weight for NVO.
Earnings fell -20.6% over the same period, trailing revenue, which points to cost or margin pressure.
Track upcoming report dates on our earnings calendar.
This is a fundamentals outlook, not a price target — we do not publish one. It describes what Novo Nordisk A/S's current financials imply about the next three to twelve months if the trends in them hold.
Constructive: Net margins of 35.3% mean that growth converts to profit rather than being spent to buy it. The main thing to watch over the next few quarters is whether those figures hold; the score is built on trailing data and will move if they do not.
These are the Novo Nordisk A/S figures that push the score up, taken straight from the most recent reported financials:
See how every metric on this NVO page — quality score, valuation, DCF scenarios, confidence, and data limitations — fits into a professional research report.
Generate My Free NVO ReportGuides to the specific measures used in this NVO analysis:
How the financial statements behind this page fit together.
Understanding P/E RatioWhat NVO's 11.0x multiple does and does not tell you.
Return on Equity (ROE)Why NVO's 59.8% return on equity matters for stock selection.
Stock Valuation MethodsHow DCF, multiples and asset-based approaches value a company like Novo Nordisk A/S.
How to Read Earnings ReportsWhere the NVO growth and margin figures on this page come from.
What Are Demand Zones?The technical side we deliberately keep out of the NVO score.
Latest SEC filings for NVO explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.
